Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04972942 · ClinicalTrials.gov registry record · Phase 1
Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA with High Risk T-Cell ALL & Lymphoma
A Phase 1 study of T-cell Acute Lymphoblastic Leukemia and T-cell Acute Lymphoblastic Lymphoma, sponsored by New York Medical College.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 16
- Study locations
NCT04972942 is a Phase 1 study of T-cell Acute Lymphoblastic Leukemia and T-cell Acute Lymphoblastic Lymphoma that is actively recruiting participants, run by New York Medical College. The registered enrollment target is 30 participants, below the 58-participant average among 6 other T-cell Acute Lymphoblastic Leukemia trials with a reported enrollment target (48% lower). The trial reports 16 study locations across 13 states.
The verdict
NCT04972942, a Phase 1 study of T-cell Acute Lymphoblastic Leukemia and T-cell Acute Lymphoblastic Lymphoma, is actively recruiting participants, sponsored by New York Medical College.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 16
- Study locations
Study Summary
A Phase I trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) for children, adolescents, and young adults (CAYA) with high risk T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LLy). Pre- and post-HCT NGS-MRD studies will be correlated with outcomes in children, adolescents, and young adults with T-ALL undergoing allogeneic HCT and post-HCT DARA treatment. The study will also evaluate T-cell repertoire and immune reconstitution prior to and following DARA post-HCT treatment and correlate with patient outcomes.
Conditions Studied
Interventions
- DRUG Daratumumab
Study Locations (16)
California
- Loma Linda University Children's Hospital - Loma Linda
- University of California - Los Angeles
- University of California - San Francisco
Florida
- University of Florida - Gainsville
- John Hopkins All Children's Hospital - St. Petersburg
Arizona
- Phoenix Children's Hospital - Phoeniz
Colorado
- Children's Hospital Colordao - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Indiana
- Riley Children's Hospital - Indianapolis
Massachusetts
- Boston Children's Hospital - Boston
Michigan
- Helen DeVos Children's Hospital - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-05-22 |
| Est. Completion | 2028-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04972942
The ClinicalTrials.gov registry entry for NCT04972942 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 58-participant average among 6 other T-cell Acute Lymphoblastic Leukemia trials with a reported enrollment target (48% lower). The listed sponsor is New York Medical College, which has 47 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with T-cell Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Daratumumab is the first listed.
NCT04972942 reports 16 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT04972942 about?
NCT04972942 is a clinical study titled "Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA with High Risk T-Cell ALL & Lymphoma". A Phase I trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) for children, adolescents, and young adults (CAYA) with high risk T-cell acute lymp...
What is the current status of trial NCT04972942?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2023-05-22. Estimated completion is 2028-09.
What conditions does trial NCT04972942 study?
This clinical trial studies the following conditions: T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma.
What interventions are being tested in trial NCT04972942?
The interventions under investigation include: Daratumumab (DRUG).
Who is sponsoring clinical trial NCT04972942?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04972942 being conducted?
This trial has 16 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for T-cell Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen
RECRUITING · Phase 1
-
Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells
RECRUITING · Phase 1
-
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
RECRUITING · Phase 2
-
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
RECRUITING · Phase 2
-
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
RECRUITING · Phase 2
-
A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)
RECRUITING · Phase 2
Explore more on PlainTrial
T-cell Acute Lymphoblastic Leukemia
All registered trials for this condition
T-cell Acute Lymphoblastic Lymphoma
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.